Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
Siva S, Ali M, Correa RJM, Muacevic A, Ponsky L, Ellis RJ, Lo SS, Onishi H, Swaminath A, McLaughlin M, Morgan SC, Cury FL, Teh BS, Mahadevan A, Kaplan ID, Chu W, Grubb W, Hannan R, Staehler M, Warner A, Louie AV. Siva S, et al. Among authors: grubb w. Lancet Oncol. 2022 Dec;23(12):1508-1516. doi: 10.1016/S1470-2045(22)00656-8. Epub 2022 Nov 16. Lancet Oncol. 2022. PMID: 36400098
A Comparative Study of Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy Using CyberKnife and Linear Accelerator-Based Volumetric Modulated Arc Therapy.
Deshpande SR, Grubb WR, Kharouta M, Zhang Y, Zheng Y, Podder TK, Towe C, Young B, Machtay M, Biswas T. Deshpande SR, et al. Among authors: grubb wr. Pract Radiat Oncol. 2022 May-Jun;12(3):200-209. doi: 10.1016/j.prro.2021.12.011. Epub 2022 Feb 15. Pract Radiat Oncol. 2022. PMID: 35177369
Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology.
Marvaso G, Jereczek-Fossa BA, Zaffaroni M, Vincini MG, Corrao G, Andratschke N, Balagamwala EH, Bedke J, Blanck O, Capitanio U, Correa RJM, De Meerleer G, Franzese C, Gaeta A, Gandini S, Garibaldi C, Gerszten PC, Gillessen S, Grubb WR, Guckenberger M, Hannan R, Jhaveri PM, Josipovic M, Kerkmeijer LGW, Lehrer EJ, Lindskog M, Louie AV, Nguyen QN, Ost P, Palma DA, Procopio G, Rossi M, Staehler M, Tree AC, Tsang YM, Van As N, Zaorsky NG, Zilli T, Pasquier D, Siva S. Marvaso G, et al. Among authors: grubb wr. Lancet Oncol. 2024 May;25(5):e193-e204. doi: 10.1016/S1470-2045(24)00023-8. Lancet Oncol. 2024. PMID: 38697165 Review.
Pretreatment and Posttreatment Tumor Metabolic Activity Assessed by FDG-PET/CT as Predictors of Tumor Recurrence and Survival Outcomes in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy.
Deshpande SR, Podder TK, Grubb W, Zhang Y, Zheng Y, Towe C, Linden P, Avril N, Biswas T. Deshpande SR, et al. Among authors: grubb w. Adv Radiat Oncol. 2023 Jul 9;9(1):101313. doi: 10.1016/j.adro.2023.101313. eCollection 2024 Jan. Adv Radiat Oncol. 2023. PMID: 38260218 Free PMC article.
149 results